Adverum Biotechnologies, Inc. ADVM witnessed a surge in its shares on Monday after the company disclosed that it had entered into an agreement to sell approximately 106.25 million shares in a private placement, raking in $127.5 million.
Key Details of the Development:
Adverum is set to offload the shares at a price per share of $1.20, representing a significant premium of about 20% to its stock’s 30-day volume-weighted average price. Furthermore, the financing is scheduled to conclude on Feb. 8.
The gross proceeds from the private placement are estimated to be approximately $127.5 million, earmarked to cover the current operating plan until late 2025, after deducting any offering related expenses.
Additionally, on Feb. 8, Adverum is set to host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec for the treatment of wet age-related macular degeneration.
The news of the $127.5 million private placement vitalized Adverum shares, driving heavy trading volumes. Benzinga Pro data reveals that more than 15.4 million shares have already been traded in the session, significantly surpassing the stock’s 100-day average volume of less than 492,000 shares.
Related News: What’s Going On With Rivian Automotive Stock?
Insight into ADVM Stock Prediction for 2024
While equity research analysts employ earnings growth and fundamental research for valuation and forecasting, trading circles often delve into technical analysis to model share price trajectory.
Some investors resort to trends to anticipate a stock’s future trajectory. For Adverum Biotechnologies, an investor could assess a stock’s long-term prospects using a moving average and trend line. If a stock stays above the moving average, often perceived as a bullish signal, investors may extrapolate that trend into the future using a trend line. Currently, the 200-day moving average for Adverum Biotechnologies stands at $1.25, which is below the current price of $1.88, as per Benzinga Pro’s data analysis.
Traders generally interpret a stock’s position above its moving average as a bullish signal and vice versa. Utilizing trend lines, investors can strategically estimate a stock’s future position if market conditions remain stable.
Overview of ADVM Price Action: According to Benzinga Pro, Adverum Biotechnologies shares have surged by 23% to $1.75 at present.
Image: Gerd Altmann from Pixabay
